The Truth and Consequences of the COURAGE Trial

Dean J. Kereiakes, Paul S. Teirstein, Ian J. Sarembock, David Holmes, Mitchell W. Krucoff, William W. O'Neill, Ron Waksman, David O. Williams, Jeffrey J. Popma, Maurice Buchbinder, Roxana Mehran, Ian T. Meredith, Jeffrey W. Moses, Gregg W. Stone

Research output: Contribution to journalReview article

92 Citations (Scopus)

Abstract

Percutaneous coronary intervention (PCI) has played an integral role in the therapeutic management strategies for patients who present with either acute coronary syndromes or stable angina pectoris. The COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation) trial enrolled patients with chronic stable angina and at least 1 significant (≥70%) angiographic coronary stenosis who were randomly assigned to an initial treatment of either PCI in conjunction with optimal medical therapy or optimal medical therapy alone. Although the initial management strategy of PCI did not reduce the risk of death, myocardial infarction, or other major cardiovascular events, improvement in angina-free status and a reduction in the requirement for subsequent revascularization was observed. An in-depth analysis of the COURAGE trial design and execution is provided.

Original languageEnglish (US)
Pages (from-to)1598-1603
Number of pages6
JournalJournal of the American College of Cardiology
Volume50
Issue number16
DOIs
StatePublished - Oct 16 2007

Fingerprint

Drug Evaluation
Percutaneous Coronary Intervention
Stable Angina
Coronary Stenosis
Therapeutics
Acute Coronary Syndrome
Myocardial Infarction

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Kereiakes, D. J., Teirstein, P. S., Sarembock, I. J., Holmes, D., Krucoff, M. W., O'Neill, W. W., ... Stone, G. W. (2007). The Truth and Consequences of the COURAGE Trial. Journal of the American College of Cardiology, 50(16), 1598-1603. https://doi.org/10.1016/j.jacc.2007.07.063

The Truth and Consequences of the COURAGE Trial. / Kereiakes, Dean J.; Teirstein, Paul S.; Sarembock, Ian J.; Holmes, David; Krucoff, Mitchell W.; O'Neill, William W.; Waksman, Ron; Williams, David O.; Popma, Jeffrey J.; Buchbinder, Maurice; Mehran, Roxana; Meredith, Ian T.; Moses, Jeffrey W.; Stone, Gregg W.

In: Journal of the American College of Cardiology, Vol. 50, No. 16, 16.10.2007, p. 1598-1603.

Research output: Contribution to journalReview article

Kereiakes, DJ, Teirstein, PS, Sarembock, IJ, Holmes, D, Krucoff, MW, O'Neill, WW, Waksman, R, Williams, DO, Popma, JJ, Buchbinder, M, Mehran, R, Meredith, IT, Moses, JW & Stone, GW 2007, 'The Truth and Consequences of the COURAGE Trial', Journal of the American College of Cardiology, vol. 50, no. 16, pp. 1598-1603. https://doi.org/10.1016/j.jacc.2007.07.063
Kereiakes DJ, Teirstein PS, Sarembock IJ, Holmes D, Krucoff MW, O'Neill WW et al. The Truth and Consequences of the COURAGE Trial. Journal of the American College of Cardiology. 2007 Oct 16;50(16):1598-1603. https://doi.org/10.1016/j.jacc.2007.07.063
Kereiakes, Dean J. ; Teirstein, Paul S. ; Sarembock, Ian J. ; Holmes, David ; Krucoff, Mitchell W. ; O'Neill, William W. ; Waksman, Ron ; Williams, David O. ; Popma, Jeffrey J. ; Buchbinder, Maurice ; Mehran, Roxana ; Meredith, Ian T. ; Moses, Jeffrey W. ; Stone, Gregg W. / The Truth and Consequences of the COURAGE Trial. In: Journal of the American College of Cardiology. 2007 ; Vol. 50, No. 16. pp. 1598-1603.
@article{4e8f9b3add2c4e08987c32c325138e22,
title = "The Truth and Consequences of the COURAGE Trial",
abstract = "Percutaneous coronary intervention (PCI) has played an integral role in the therapeutic management strategies for patients who present with either acute coronary syndromes or stable angina pectoris. The COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation) trial enrolled patients with chronic stable angina and at least 1 significant (≥70{\%}) angiographic coronary stenosis who were randomly assigned to an initial treatment of either PCI in conjunction with optimal medical therapy or optimal medical therapy alone. Although the initial management strategy of PCI did not reduce the risk of death, myocardial infarction, or other major cardiovascular events, improvement in angina-free status and a reduction in the requirement for subsequent revascularization was observed. An in-depth analysis of the COURAGE trial design and execution is provided.",
author = "Kereiakes, {Dean J.} and Teirstein, {Paul S.} and Sarembock, {Ian J.} and David Holmes and Krucoff, {Mitchell W.} and O'Neill, {William W.} and Ron Waksman and Williams, {David O.} and Popma, {Jeffrey J.} and Maurice Buchbinder and Roxana Mehran and Meredith, {Ian T.} and Moses, {Jeffrey W.} and Stone, {Gregg W.}",
year = "2007",
month = "10",
day = "16",
doi = "10.1016/j.jacc.2007.07.063",
language = "English (US)",
volume = "50",
pages = "1598--1603",
journal = "Journal of the American College of Cardiology",
issn = "0735-1097",
publisher = "Elsevier USA",
number = "16",

}

TY - JOUR

T1 - The Truth and Consequences of the COURAGE Trial

AU - Kereiakes, Dean J.

AU - Teirstein, Paul S.

AU - Sarembock, Ian J.

AU - Holmes, David

AU - Krucoff, Mitchell W.

AU - O'Neill, William W.

AU - Waksman, Ron

AU - Williams, David O.

AU - Popma, Jeffrey J.

AU - Buchbinder, Maurice

AU - Mehran, Roxana

AU - Meredith, Ian T.

AU - Moses, Jeffrey W.

AU - Stone, Gregg W.

PY - 2007/10/16

Y1 - 2007/10/16

N2 - Percutaneous coronary intervention (PCI) has played an integral role in the therapeutic management strategies for patients who present with either acute coronary syndromes or stable angina pectoris. The COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation) trial enrolled patients with chronic stable angina and at least 1 significant (≥70%) angiographic coronary stenosis who were randomly assigned to an initial treatment of either PCI in conjunction with optimal medical therapy or optimal medical therapy alone. Although the initial management strategy of PCI did not reduce the risk of death, myocardial infarction, or other major cardiovascular events, improvement in angina-free status and a reduction in the requirement for subsequent revascularization was observed. An in-depth analysis of the COURAGE trial design and execution is provided.

AB - Percutaneous coronary intervention (PCI) has played an integral role in the therapeutic management strategies for patients who present with either acute coronary syndromes or stable angina pectoris. The COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation) trial enrolled patients with chronic stable angina and at least 1 significant (≥70%) angiographic coronary stenosis who were randomly assigned to an initial treatment of either PCI in conjunction with optimal medical therapy or optimal medical therapy alone. Although the initial management strategy of PCI did not reduce the risk of death, myocardial infarction, or other major cardiovascular events, improvement in angina-free status and a reduction in the requirement for subsequent revascularization was observed. An in-depth analysis of the COURAGE trial design and execution is provided.

UR - http://www.scopus.com/inward/record.url?scp=34948893828&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34948893828&partnerID=8YFLogxK

U2 - 10.1016/j.jacc.2007.07.063

DO - 10.1016/j.jacc.2007.07.063

M3 - Review article

C2 - 17936161

AN - SCOPUS:34948893828

VL - 50

SP - 1598

EP - 1603

JO - Journal of the American College of Cardiology

JF - Journal of the American College of Cardiology

SN - 0735-1097

IS - 16

ER -